A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: DRUG: Bevacizumab|DRUG: Paclitaxel
Sponsor: Hoffmann-La Roche